WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001029075) A NOVEL POLYPEPTIDE-G-PROTEIN ACTIVATING PROTEIN 129 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/029075    International Application No.:    PCT/CN2000/000329
Publication Date: 26.04.2001 International Filing Date: 16.10.2000
IPC:
A61K 38/00 (2006.01), C07K 14/47 (2006.01)
Applicants: SHANGHAI BIO ROAD GENE DEVELOPMENT LTD. [CN/CN]; 3rd Building, 12th Floor, No. 1111 Zhongshan Bei Er Road, Shanghai 200092 (CN) (For All Designated States Except US).
MAO, Yumin [CN/CN]; (CN) (For US Only).
XIE, Yi [CN/CN]; (CN) (For US Only)
Inventors: MAO, Yumin; (CN).
XIE, Yi; (CN)
Agent: SHANGHAI HUA DONG PATENT AGENCY; 319 Yue Yang Road, Shanghai 200031 (CN)
Priority Data:
99 1 16986.7 18.10.1999 CN
Title (EN) A NOVEL POLYPEPTIDE-G-PROTEIN ACTIVATING PROTEIN 129 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
(FR) NOUVEAU POLYPEPTIDE, PROTEINE 129 ACTIVANT LA PROTEINE G, ET POLYNUCLEOTIDE CODANT POUR CE POLYPEPTIDE
Abstract: front page image
(EN)The invention discloses a newly identified polypeptide which is namely G-protein activating protein 129 and the polynucleotide encoding said polypeptide and a process for producing them by recombinant methods. The invention also discloses that the polypeptide could be used for the treatment of various kinds of diseases, such as cancer, immune disease, metabolic disorder, hypogenesis and visual disturbance. The antagonist of the polypeptide and the therapeutic use of the same is also disclosed. In addition, it refers to the use of the polynucleotide encoding said polypeptide 129.
(FR)L'invention concerne un nouveau polypeptide, une protéine 129 activant la protéine G, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de maladies immunitaires, de troubles métaboliques, d'hypogenèse et de troubles visuels. L'invention concerne aussi l'agoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour la protéine 129 activant la protéine G.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)